For many years, fluorosis has been known as a worldwide disease which seriously diminishes quality of life through skeletal embrittlement and hepatic damage. Aiming to develop novel drugs for simultaneous fluorosis diagnosis and therapy, in this work we explore the feasibility of a novel pyrogallic acid- 
Introduction
Fluorine, possessing an important role in keeping bones strong, is an essential macroelement in living systems. 1 It is mostly present in its ionic state (F À ), which can be accumulated via both exposure and intake. However, the over-accumulation of F À causes uorosis, which has symptoms like skeletal embrittlement and hepatic damage, including endocrine disorder, abnormal calcium accumulation, and teeth staining. 2, 3 It is noteworthy that F À can be cleared from blood within a short period by combination with albumin, a typical type of protein in serum, making F À difficult to capture and metabolise. 4 Therefore, for the development of novel drugs towards uorosis therapy, drugs should have a strong interaction with F À to capture it from albumins. Typically, the clearance of F À from blood is achieved by the use of calcium and magnesium salts, producing insoluble depositions such as CaF 2 and MgF 2 . 5 A recent advance also demonstrated that transition metal ions and F À can form stable complexes via coordinate interaction and hence decrease the F À concentration. 6 Moreover the complexes, possessing behavior like that of macromolecular drugs, can be excreted from the kidney through urine, which further shortens the F À excretion period. 7 Apart from their therapeutic efficiency, traditional drugs lack the ability to quantify F À concentration for the purposes of diagnosis and monitoring of the therapeutic process. As a result of these shortcomings, a new type of drug is required for the integration of uorosis therapy and diagnosis. Nanomaterials have been explored as excellent vehicles for drug delivery. [8] [9] [10] [11] Therefore, nanomaterials modied with molecules containing transition metal ions have the potential to serve as nanodrugs for uorosis therapy. Among all transition metal complexes, pyrogallic acid-titanium(IV) complex (PA-Ti) possesses high stability, high biocompatibility, and a low interaction with other biomolecules, which is promising for their bioapplication efficacy. Besides, the nanodrugs, equipped with the luminescence imaging function, also show great potential for the dynamic monitoring of F À concentration within a therapeutic process. [12] [13] [14] Upconversion nanoprobes (UCNPs), excited by near-infrared (NIR) radiation, have been explored and studied as bioimaging nanophosphors for many years due to their high luminescence penetration, low autoluminescence from biosamples, high photostability, and adjustable multiple emission bands. [15] [16] [17] [18] [19] These advantages promised UCNPs a bright future in not only bioimaging but molecule detection and biolabeling. [20] [21] [22] [23] [24] Due to the surface quenching effect, an inner shell was required to minimize the energy loss and improve the luminescence efficiency. 25 Therefore, the construction of core-shell UCNPs is much more favorable for bioapplications. Notably, if modied metal ioncontaining molecules are close enough to the UCNPs, which possess strong absorbance in the wavelength range of the upconversion luminescence (UCL) emission, a Förster resonance energy transfer (FRET) occurs between them and the UCL is quenched accordingly. [26] [27] [28] By calculating the d-d transition energy of PA-Ti and observing its absorbance spectrum, it was found that the absorbance overlapped with the blue emission of Tm-doped UCNPs, which allowed FRET generation. With F À addition the modied PA-Ti decomposed, which led to the absorbance decreasing, FRET degeneration, and UCL recovery. Accordingly, a relationship can be established between the UCL intensity of PA-Ti-modied UCNPs and F À concentration. On account of the above facts, utilizing the strong coordinate interaction between titanium ions (Ti   4+ ) and F À , a novel UCNP-based nanoprobe with rational modication can be used for uorosis therapy and F À concentration monitoring simultaneously.
In this work, a novel PA-Ti-modied NaLuF 4 :Yb,Tm@NaLuF 4 (UCNP-PA-Ti) was developed for uorosis theranostics. The Ti 4+ can be complexed with F À , which results in PA-Ti decomposition, FRET weakening, and UCL recovery in the presence of F À (Fig. 1A) . The detection limit, linear range, and selectivity for F À detection were studied in vitro, as well as their potential for uorosis therapy. Further effort was made to illustrate the ex vivo uorosis diagnosis capacity and the in vivo theranostics efficiency of UCNP-PA-Ti using mice as a model. This work, by simultaneously achieving uorosis therapy and F À concentration monitoring, provides a new insight to the development of nanodrugs towards uorosis theranostics.
Experimental section
Preparation of pyrogallic acid-titanium(IV) modied NaLuF 4 :Yb,Tm@NaLuF 4 (UCNP-PA-Ti)
The NaLuF 4 :Yb,Tm@NaLuF 4 upconversion nanoparticles (UCNPs) were prepared via a typical solvothermal method.
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The bare UCNPs were obtained by removing oleic acid ligands on the surface via a reported ligand exchange method using nitrosonium tetrauoroborate. 31 Further modication of the pyrogallic acid-titanium(IV) complex was carried out in a bare UCNP suspension to obtain UCNP-PA-Ti. Please see ESI † for experimental details. 
Results and discussion

Preparation and characteristics of the UCNP-PA-Ti nanoprobe
The core-shell NaLuF 4 :Yb,Tm@NaLuF 4 upconversion nanoparticles (UCNP) were developed via a typical solvothermal method. The transmission electron microscopy (TEM) images show that NaLuF 4 :Yb,Tm has a uniform morphography with a narrow size distribution of 18.43 AE 2.63 nm (Fig. 1B and S1 †). Aer NaLuF 4 shell coating, the size of the UCNPs increased to 24.72 AE 2.77 nm, which illustrated that the UCNPs with coreshell structure had been successfully prepared ( Fig. 1C and S2 †) .
Importantly, the upconversion luminescence (UCL) intensity in both visible and near-infrared (NIR) regions improved aer NaLuF 4 shell coating, which can be attributed to the inhibition of multiphonon relaxation between the doping element (Yb 3+ and Tm 3+ ) in the UCNPs and absorbed H 2 O molecules (Fig. S3 †) . 33 Moreover, X-ray diffraction (XRD) patterns suggest that the UCNPs possess a highly crystalline hexagonal phase, corresponding to the standard card of b-NaLuF 4 (JCPDS: 027-0726, Fig. 1D ). The high-resolution TEM (HR-TEM) image and selected area electron diffraction (SAED) patterns also conrmed this nding (Fig. S4 †) .
The pyrogallic acid-titanium(IV) complex (PA-Ti) was then modied on the UCNPs using a ligand-exchange method (UCNP-PA-Ti). The successful modication can be identied from the ultraviolet-visible-near infrared (UV-vis-NIR) spectra and the Föurier transmission infrared (FTIR) spectra (Fig. 1E and S5 †). The UV-vis-NIR spectra show an intense absorbance band in the visible spectral region, which is attributed to d-d band transitions between the lower energy (t 2g ) and higher energy (e g ) levels of Ti 4+ ( Fig. 1E and G (Fig. 1F and G) . Moreover, the obtained UCNP-PA-Ti showed excellent solubility and stability in various biological uids and pH conditions. They also possessed high photostability under laser irradiation (Table S1 , Fig. S6 and 7 †). As a result of these ndings, UCNP-PA-Ti was successfully prepared as a potential nanophosphor for further F À capture and detection studies.
Capture efficiency and UCL detection of F À by UCNP-PA-Ti
As a novel nanoprobe for uorosis theranostics, UCNP-PA-Ti is required to have a short F À capture period and a high capture efficiency in albumin-rich biological environments. Therefore, further efforts were made to improve the F À capture properties of UCNP-PA-Ti. In the presence of F À , the decomposition of modied PA-Ti complex can be observed both in the UV-vis-NIR spectra and with the naked eye due to the stronger interaction between Ti 4+ and F À than the phenol groups in PA ( Fig. 2A) (Fig. 2D) . The high F À capture efficiency and short capture period are advantageous for uorosis therapy, as well as the rapid and sensitive detection of F À .
According to previous reports, ratiometric UCL detection strategies provide a straightforward means for facing the difficulties of single-band UCL detection by avoiding inuences caused by concentration, absorption, scattering, and light sources. 34, 35 To illustrate the capability of UCNP-PA-Ti for ratiometric F À UCL detection, the UCL spectra of UCNP-PA-Ti were measured aer adding F À solutions of various concentrations. With increasing F À concentration, the luminescence of UCNP-PA-Ti in the 400-500 nm range recovered and the luminescence centered at 800 nm showed no obvious change with the addition of F À , which can be explained by the symmetric octahedral structure of formed [TiF 6 ] 2À and the inhibition of d-d transitions (Fig. 3A) . Besides, it can be found that the ratio of the intensities at 470 nm and 800 nm, abbreviated as I(470)/I(800), has a positive relationship with the F À concentration of the added solution (Fig. 3B) . (Table S3 †) . Moreover, the recovery of the blue emission (470 nm) of UCNP-PA-Ti can also be observed by the naked eye, which is favorable for the development of a potential paper-based device for F À detection (Fig. 3D ).
The feasibility of UCNP-PA-Ti for ratiometric UCL imaging of F À was also studied to explore its potential for further application. The UCL signals were collected at 400-600 nm, 600-700 nm, and 800 AE 12 nm by a charge-coupled device ( Fig. 3E and F) . With increasing concentration of F À , the UCL signal intensity in the range of 400-600 nm increased accordingly. Meanwhile, 600-700 nm and 800 AE 12 nm UCL signal intensities showed no observable change (Table S4 †) . Besides, UCNP-PA-Ti had no response to typical ions, amino acids, biomolecules, and proteins from living systems (Fig. 3G-I , S9 and S10 †). Importantly, other anions showed a negative inu-ence on F À detection of UCNP-PA-Ti (Fig. S11 †) . Besides, soluble uoride species exhibited no inuence on the quantication of F À (Fig. S12 †) . Due to the penetration difference between 650 nm and 800 nm UCL in bioimaging, it is rational to use 650 nm in cell imaging and 800 nm in small animal imaging as references. As a result of these advantages, UCNP-PA-Ti is a promising nanoprobe for use in the ratiometric UCL imaging of F À both in vitro and in vivo.
Fluorosis theranostics and F À concentration monitoring
Fluorosis, caused by continuous high F À uptake, can induce a great many chronic diseases such as skeletal deformity, arthralgia, and liver brosis. 36 Therefore, the use of uorosis theranostics in the early stages of disease is essential. With F À responsive UCL emissions, high F À capture efficiency, and the ability to produce a soluble metabolite with a small hydrodiameter, UCNP-PA-Ti has great potential in both uorosis diagnosis and rapid renal F À excretion (Fig. S13 and 14 †) . To demonstrate their uorosis theranostic properties, ratiometric UCL imaging of F À was performed. Live hepatocyte (CCC-HEL-1 cell line) was used as a cell model for UCL cell imaging. Aer incubation with UCNP-PA-Ti, strong UCL can be observed in the cytoplasm of live hepatocyte, demonstrating that the nanoprobe can be rapidly uptaken by cells and accumulate in F À -containing electrolytes, which is favorable for F À detection (Fig. 4A ). Importantly, with the increase in pretreated F À concentration, UCL intensity in live hepatocyte collected in the blue channel (400-600 nm, abbreviated as B) is enhanced, while the red channel (650 AE 15 nm, abbreviated as R) showed no obvious change. The blue and red UCL emission intensities obtained from cells were then quantied and the B/R ratio was calculated as a function of increasing F À concentration (Fig. 4B) . It was found that the B/R ratio is positively correlated with F À concentration, increasing from 1.029 to 3.315, which can be veried as being signicant. This result illustrated not only the highly efficient reaction between the nanoprobes and F À in cells, but the feasibility of UCNP-PA-Ti for F À detection via ratiometric UCL imaging in cells. Further efforts were made on in vivo ratiometric UCL imaging using mice suffering from uorosis as a model. A strong UCL signal can be observed in mice that have received an intravenous injection of UCNP-PA-Ti (Fig. 5A and B) . It is noteworthy that the blue UCL signal collected in the range 400-600 nm from normal mice was obviously lower than that from mice suffering from uorosis, while the NIR UCL signal at 800 AE 12 nm (abbreviated as N) showed no signicant difference. The B/N ratio was calculated to illustrate the feasibility for F À monitoring in vivo. Obviously, a higher B/N ratio was found for mice suffering from uorosis than for normal mice, which suggested that UCNP-PA-Ti can react with F À in vivo, resulting in the recovery of blue UCL emission. The UCL images of dissected organs suggested that UCNP-PA-Ti had high retention in the reticuloendothelial system of mice, such as the liver and spleen (Fig. 5C and D) , which corresponds to the biodistribution of UCNP-PA-Ti (inset in Fig. 5E ). It was also found that UCNP-PA-Ti accumulated in the kidney, which might be a result of their prolonged blood circulation time and relatively low hydrodiameter (Fig. 5E ). Corresponding to the UCL images in vivo and biodistribution of UCNP-PA-Ti, the blue UCL emission intensity in dissected organs obtained from mice suffering from uorosis was signicantly high, while that from normal mice was low (Fig. 5F ). To quantify the F À ratiometric imaging feasibility, the B/N ratio in organs was calculated. It was found that the B/N ratio for the organs of mice suffering from uorosis (0.781 AE 0.088) was signicantly higher than that of the organs of normal mice (0.311 AE 0.073), which was in good agreement with the ratiometric UCL imaging in vivo (Fig. 5G) .
The above results strongly demonstrate the feasibility of UCNP-PA-Ti for F À detection and ratiometric imaging in vivo. Therefore, UCL imaging was used to monitor standard F À concentration within the therapeutic process.
Since UCNP-PA-Ti can effectively react with F À and showed a sensitive UCL responsive in vivo, the UCL imaging-monitored therapeutic efficiency was then studied using mice suffering from uorosis as a model. Within the uorosis therapeutic process, mice suffering from uorosis received an intravenous injection of UCNP-PA-Ti. UCL images were taken and humoral samples were collected at various time points (Fig. 6A) . Aer intravenous injection, UCNP-PA-Ti circulated in the vessels and captured F À in the blood, forming stable complexes and decreasing free F À concentration, and accelerating metabolism.
As shown in Fig. 6B , blue UCL emission intensity decreased accordingly while the NIR UCL emission showed no observable change. More importantly, not only the blue emission intensity but the B/N ratio decreased from 0.57 to 0.28 throughout the therapeutic process (Fig. 6C-E) . The time-dependent decrease of blue UCL emission intensity, as well as B/N, can be explained by the blood F À concentration gradually decreasing aer receiving the UCNP-PA-Ti injection. With a low F À concentration in the blood, only a few PA-Ti complexes would be decomposed by F À , which resulted in low blue UCL recovery in UCNP-PA-Ti accumulated organs. To further demonstrate the therapeutic efficiency of UCNP-PA-Ti as nanodrugs for uorosis therapy, three typical indexes were determined, namely, the F À concentration in blood and urine, as well as the F À amount in feces. Within a 7 day therapeutic period, the F À concentration in blood continuously decreased and essentially returned to normal (Fig. 6F ), compared to normal mice. However, the blood F À concentration in those mice receiving no therapy remained high, a signicant difference to those receiving therapy. The F À amount in feces and F À concentration in urine, generated from mice suffering from uorosis that received therapy, were higher than in those receiving no therapy for the rst few days and then decreased rapidly in the last period ( Fig. 6G and H) . Moreover, the outstanding stability of the [TiF 6 ] 2À complex in urine ensured the safety of its renal metabolic pathway. These phenomena can be explained due to the highly efficient uoride expulsion and accelerated uorine metabolism through the liver and kidney. These results provide solid evidence for the high uorosis therapeutic efficiency of UCNP-PA-Ti in living systems with rapid and efficient metabolism.
Cytotoxicity and biocompatibility in vivo
Though the safety of rare-earth upconversion nanoprobes for bioapplications has been demonstrated previously, a detailed toxicity study of the designed UCNP-PA-Ti was still required.
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The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to evaluate their cytotoxicity. CCC-HEL-1 cells remained of high cellular viability (>90%) within incubation processes of 24 and 48 h with various concentrations of UCNP-PA-Ti, which demonstrated the lack of signicant cytotoxicity of UCNP-PA-Ti to normal cells (Fig. S15A †) . Further efforts were undertaken, focusing on biocompatibility in vivo. Healthy mice were given an intravenous injection of UCNP-PA-Ti (20 mg kg
À1
) and monitored for 30 days. The mice receiving the UCNP-PA-Ti injection neither died nor showed observable abnormal behavior. Moreover, complete blood panel tests and serum biochemistry assays were performed, which mainly focused on liver and kidney functions, testing indicators including alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), total protein (TP), albumin (ALB), and creatinine (CREA) (Fig. S15B-D †) . The results illustrated that no signicant content differences can be found between mice receiving PBS (Blank) or a UCNP-PA-Ti injection within 30 days, suggesting that UCNP-PA-Ti wouldn't induce palpable liver or kidney function disturbances. In addition, hematoxylin-eosin (H&E) stained histological examinations of primary organs -these being the heart, liver, spleen, lung, and kidney -suggested that UCNP-PA-Ti wouldn't induce organ morphology abnormity and pathological changes (Fig. S16 †) . As a result of the above systematic investigation, the safety of UCNP-PA-Ti for uorosis theranostics at our tested dosage range has been solidly conrmed. 
